Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

International multidisciplinary expert panel consensus on breast reconstruction and radiotherapy.

Nava MB, Benson JR, Audretsch W, Blondeel P, Catanuto G, Clemens MW, Cordeiro PG, De Vita R, Hammond DC, Jassem J, Lozza L, Orecchia R, Pusic AL, Rancati A, Rezai M, Scaperrotta G, Spano A, Winters ZE, Rocco N.

Br J Surg. 2019 Sep;106(10):1327-1340. doi: 10.1002/bjs.11256. Epub 2019 Jul 18.

PMID:
31318456
2.

Tobacco smoking after diagnosis of cancer: clinical aspects.

Jassem J.

Transl Lung Cancer Res. 2019 May;8(Suppl 1):S50-S58. doi: 10.21037/tlcr.2019.04.01. Review.

3.

Lung cancer: a preventable disease.

Jassem J.

Transl Lung Cancer Res. 2019 May;8(Suppl 1):S1-S2. doi: 10.21037/tlcr.2019.04.13. No abstract available.

4.

Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC.

Rutkowski J, Saad ED, Burzykowski T, Buyse M, Jassem J.

J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30415-0. doi: 10.1016/j.jtho.2019.05.030. [Epub ahead of print]

PMID:
31163279
5.

Folate/homocysteine metabolism and lung cancer risk among smokers.

Stanisławska-Sachadyn A, Borzyszkowska J, Krzemiński M, Janowicz A, Dziadziuszko R, Jassem J, Rzyman W, Limon J.

PLoS One. 2019 Apr 2;14(4):e0214462. doi: 10.1371/journal.pone.0214462. eCollection 2019.

6.

Prognostic value of broad-spectrum keratin clones AE1/AE3 and CAM5.2 in small cell lung cancer patients undergoing pulmonary resection.

Badzio A, Czapiewski P, Gorczyński A, Szczepańska-Michalska K, Haybaeck J, Biernat W, Jassem J.

Acta Biochim Pol. 2019 Feb 22;66(1):111-114. doi: 10.18388/abp.2018_2773.

7.

Indeed, Nuance Matters.

Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J.

J Thorac Oncol. 2019 Jan;14(1):e16-e17. doi: 10.1016/j.jtho.2018.11.004. No abstract available.

PMID:
30579550
8.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.

J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.

PMID:
30475668
9.

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

Wrona A, Dziadziuszko R, Jassem J.

Cancer Treat Rev. 2018 Dec;71:59-67. doi: 10.1016/j.ctrv.2018.10.011. Epub 2018 Oct 21. Review.

PMID:
30366200
10.

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Begum M, Lewison G, Jassem J, Mixich V, Cufer T, Nurgozhin T, Shabalkin P, Kutluk T, Voko Z, Radosavljevic D, Vrdoljiak E, Eniu A, Walewski J, Aggarwal A, Lawler M, Sullivan R.

Eur J Cancer. 2018 Nov;104:127-136. doi: 10.1016/j.ejca.2018.08.024. Epub 2018 Oct 20.

PMID:
30347288
11.

Pharmacotherapy of pain in cancer patients - recommendations of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons.

Wordliczek J, Kotlińska-Lemieszek A, Leppert W, Woroń J, Dobrogowski J, Krajnik M, Przeklasa-Muszyńska A, Jassem J, Drobnik J, Wrzosek A, Janecki M, Pyszkowska J, Kocot-Kępska M, Zajączkowska R, Filipczak-Bryniarska I, Boczar K, Jakowicka-Wordliczek J, Malec-Milewska M, Kübler A, Suchorzewski M, Mordarski S, Dziki A, Paśnik K.

Pol Przegl Chir. 2018 Aug 31;90(4):55-84. doi: 10.5604/01.3001.0012.2904.

12.

Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.

Vrdoljak E, Bodoky G, Jassem J, Popescu R, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kopečková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Sikic B.

Oncologist. 2019 Jan;24(1):e30-e37. doi: 10.1634/theoncologist.2018-0093. Epub 2018 Sep 4.

PMID:
30181313
13.

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.

Jassem J.

Lancet Respir Med. 2018 Nov;6(11):808-810. doi: 10.1016/S2213-2600(18)30307-2. Epub 2018 Aug 24. No abstract available.

PMID:
30150013
14.

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.

Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, Press MF.

Breast Cancer Res Treat. 2018 Nov;172(2):327-338. doi: 10.1007/s10549-018-4889-5. Epub 2018 Aug 17.

15.

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.

Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS.

Nat Commun. 2018 Jul 13;9(1):2705. doi: 10.1038/s41467-018-05030-w.

16.

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F.

Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.

PMID:
29880291
17.

Systemic therapy for cervical carcinoma - current status.

Serkies K, Jassem J.

Chin J Cancer Res. 2018 Apr;30(2):209-221. doi: 10.21147/j.issn.1000-9604.2018.02.04.

18.

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.

Duchnowska R, Loibl S, Jassem J.

Cancer Treat Rev. 2018 Jun;67:71-77. doi: 10.1016/j.ctrv.2018.05.004. Epub 2018 May 9. Review.

PMID:
29772459
19.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
20.

Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

Skrzypski M, Jassem J.

Cancer Treat Rev. 2018 May;66:114-121. doi: 10.1016/j.ctrv.2018.04.001. Epub 2018 Apr 5. Review.

PMID:
29738940
21.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
22.

"Teachable Moment" Interventions in Lung Cancer: Why Action Matters.

Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J.

J Thorac Oncol. 2018 May;13(5):603-605. doi: 10.1016/j.jtho.2018.02.020. No abstract available.

23.

MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.

Filipska M, Skrzypski M, Czetyrbok K, Stokowy T, Stasiłojć G, Supernat A, Jassem J, Żaczek AJ, Bigda J.

Lung Cancer. 2018 Apr;118:111-118. doi: 10.1016/j.lungcan.2018.02.002. Epub 2018 Feb 6.

PMID:
29571988
24.

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.

Müller V, Clemens M, Jassem J, Al-Sakaff N, Auclair P, Nüesch E, Holloway D, Shing M, Bang YJ.

BMC Cancer. 2018 Mar 15;18(1):295. doi: 10.1186/s12885-018-4183-2.

25.

Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.

Hryciuk B, Szymanowski B, Romanowska A, Salt E, Wasąg B, Grala B, Jassem J, Duchnowska R.

Oncol Lett. 2018 Feb;15(2):1912-1916. doi: 10.3892/ol.2017.7473. Epub 2017 Nov 22.

26.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.

Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.

PMID:
29433850
27.

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.

Duchnowska R, Sperinde J, Czartoryska-Arłukowicz B, Myśliwiec P, Winslow J, Radecka B, Petropoulos C, Demlova R, Orlikowska M, Kowalczyk A, Lang I, Ziółkowska B, Dębska-Szmich S, Merdalska M, Grela-Wojewoda A, Żawrocki A, Biernat W, Huang W, Jassem J.

Oncotarget. 2017 Oct 24;8(61):104149-104159. doi: 10.18632/oncotarget.22027. eCollection 2017 Nov 28.

28.

Dual HER2 Blockade.

Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M.

Breast Care (Basel). 2017 Oct;12(5):345-349. doi: 10.1159/000484226. Epub 2017 Oct 30. No abstract available.

29.

Serum lipid profile discriminates patients with early lung cancer from healthy controls.

Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Lung Cancer. 2017 Oct;112:69-74. doi: 10.1016/j.lungcan.2017.07.036. Epub 2017 Aug 1.

PMID:
29191603
30.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

31.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

32.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum. No abstract available.

33.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.

J Clin Oncol. 2017 Oct 20;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629. Epub 2017 Aug 30.

PMID:
28854067
34.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

35.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

36.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308. Erratum in: Ann Oncol. 2018 Oct 1;29(10):2153. Ann Oncol. 2019 Jan 9;:.

37.

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.

Roś-Mazurczyk M, Wojakowska A, Marczak Ł, Polański K, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Acta Biochim Pol. 2017;64(3):513-518. doi: 10.18388/abp.2017_1517. Epub 2017 Aug 12.

38.

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O.

J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28.

PMID:
28753384
39.

Post-mastectomy radiation therapy after breast reconstruction: Indications, timing and results.

Jassem J.

Breast. 2017 Aug;34 Suppl 1:S95-S98. doi: 10.1016/j.breast.2017.06.037. Epub 2017 Jun 30. Review.

PMID:
28673536
40.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.

41.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation.

Senkus E, Szade J, Pieczyńska B, Kunc M, Pliszka A, Jassem J.

Histol Histopathol. 2018 Jan;33(1):55-64. doi: 10.14670/HH-11-887. Epub 2017 Mar 9.

PMID:
28276034
42.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133. Epub 2017 Mar 8. Erratum in: Oncologist. 2017 Oct;22(10 ):1281.

43.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

44.

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

Serkies K, Jaśkiewicz J, Dziadziuszko R, Jassem J.

J Contemp Brachytherapy. 2016 Dec;8(6):492-496. doi: 10.5114/jcb.2016.64512. Epub 2016 Dec 9.

45.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, Whittaker S, Blanke C.

Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3. doi: 10.1016/j.clcc.2016.08.008. Epub 2016 Sep 7.

PMID:
28038865
46.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH.

Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.

PMID:
27975152
47.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.

Szutowicz-Zielińska E, Konopa K, Kowalczyk A, Suszko-Każarnowicz M, Duchnowska R, Szczęsna A, Ratajska M, Sowa A, Limon J, Biernat W, Burzykowski T, Jassem J, Dziadziuszko R.

Oncotarget. 2017 Mar 7;8(10):17270-17278. doi: 10.18632/oncotarget.13793.

48.

Highlights from the San Antonio Breast Cancer Symposium 2015.

Jassem J.

ESMO Open. 2016 Feb 26;1(1):e000043. eCollection 2016.

49.

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

Pavlidis N, Alba E, Berardi R, Bergh J, El Saghir N, Jassem J, Kosty M, Lopez RI, Lotz JP, Österlund P, Purkalne G, Dittrich C.

ESMO Open. 2016 Jan 18;1(1):e000004. eCollection 2016. No abstract available.

50.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14.

Supplemental Content

Loading ...
Support Center